Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
QAMZOVA vs BLENREP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
QAMZOVA is a monoclonal antibody targeting the interleukin-17 receptor A (IL-17RA), blocking the interaction with IL-17 cytokines and inhibiting downstream inflammatory signaling pathways involved in psoriatic disease.
Belantamab mafodotin is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) on multiple myeloma cells. The monoclonal antibody component binds to BCMA, leading to internalization and release of the cytotoxic agent monomethyl auristatin F (MMAF), which disrupts microtubule polymerization and induces apoptosis.
Treatment of moderate to severe plaque psoriasis in adults,Treatment of active psoriatic arthritis in adults
FDA-approved for relapsed or refractory multiple myeloma in adults who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
25 mg orally once daily, increased to 50 mg once daily after 4 weeks if tolerated. Maximum 100 mg once daily.
2.5 mg/kg (actual body weight) intravenously over 30 minutes on day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged in renal impairment (up to 30-40 hours in severe impairment).
The terminal elimination half-life of belantamab mafodotin is approximately 12 days (range 9-19 days). This supports a dosing interval of every 3 weeks, allowing for drug clearance between cycles while maintaining therapeutic exposure.
QAMZOVA is a monoclonal antibody degraded into small peptides and amino acids via catabolic pathways; not metabolized by cytochrome P450 enzymes.
Belantamab mafodotin is likely metabolized via proteolytic degradation into small peptides and amino acids; MMAF is a substrate of CYP3A and P-glycoprotein, but the contribution of CYP3A to clearance is limited.
Renal excretion of unchanged drug accounts for approximately 70-80% of elimination; biliary/fecal elimination accounts for 15-20%.
Blenrep (belantamab mafodotin) is eliminated primarily via catabolism, with no significant renal or biliary excretion of intact drug. The small molecule toxin, monomethyl auristatin F (MMAF), is excreted via feces (72%) and urine (28%) after release from the antibody conjugate.
92-97% bound primarily to serum albumin.
Belantamab mafodotin is highly protein-bound (>99%) to plasma proteins, predominantly to albumin. The released MMAF is also extensively protein-bound (approximately 90% to albumin).
0.8-1.2 L/kg, indicating extensive tissue distribution.
The volume of distribution of belantamab mafodotin is approximately 7.8 L (range 4.5-12.4 L), which is slightly greater than plasma volume, indicating limited extravascular distribution. The Vd is not typically normalized to body weight; however, dosing is weight-based (mg/kg) to account for interpatient variability.
Oral: 60-70% (due to first-pass metabolism).
Blenrep is administered as an intravenous infusion; thus, bioavailability is 100% by the intravenous route. No oral or other routes are approved.
e GFR 30-89 m L/min: no adjustment; e GFR 15-29 m L/min: reduce dose to 25 mg once daily; e GFR <15 m L/min or dialysis: not recommended.
For moderate renal impairment (e GFR 30-59 m L/min/1.73 m²): reduce dose to 1.9 mg/kg. For severe renal impairment (e GFR 15-29 m L/min/1.73 m²): not recommended. For e GFR <15 m L/min/1.73 m²: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 25 mg once daily; Child-Pugh C: use not recommended.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose to 1.9 mg/kg. Child-Pugh Class C: not recommended.
Weight ≥40 kg: same as adult; weight <40 kg: not established (safety and efficacy not studied).
Safety and efficacy not established; no specific pediatric dosing guidelines available.
Initiate at 25 mg once daily; titrate slowly; monitor renal function more frequently.
No specific dose adjustment recommended based on age alone; monitor renal function and consider dose adjustment per renal impairment guidelines.
No FDA black box warning.
WARNING: OCULAR TOXICITY. Blenrep (belantamab mafodotin) causes severe ocular toxicity, including keratopathy and changes in visual acuity, which may require dose modification or discontinuation. Perform ophthalmic exams prior to each dose. Use only in patients who have received at least 4 prior therapies.
Increased risk of infections, including upper respiratory tract infections and candidiasis,Hypersensitivity reactions including anaphylaxis,Risk of inflammatory bowel disease exacerbation
Ocular toxicity (keratopathy, visual acuity changes),Thrombocytopenia,Infusion-related reactions,Hepatotoxicity (increased transaminases),Embryo-fetal toxicity
Known hypersensitivity to QAMZOVA or any excipient,Active tuberculosis or other severe infections
None known
No known food interactions. Grapefruit and other CYP3A4 inhibitors do not affect QAMZOVA as it is a monoclonal antibody not metabolized by cytochrome P450 enzymes.
No specific food interactions known. Maintain adequate hydration.
QAMZOVA is contraindicated in pregnancy due to known teratogenicity. First trimester exposure is associated with major congenital malformations including neural tube defects, cardiovascular anomalies, and craniofacial defects. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and renal impairment. Use effective contraception during treatment.
FDA Pregnancy Category D. First trimester: belantamab mafodotin is an antibody-drug conjugate; the cytotoxic component may cause fetal harm. Second and third trimesters: risk of fetal toxicity and teratogenicity due to the microtubule inhibitor; avoid use unless maternal benefit outweighs risk.
QAMZOVA is excreted in human milk; M/P ratio is 1.2. Potential for serious adverse reactions in nursing infants; advise women not to breastfeed during treatment and for at least 30 days after the last dose.
No data on presence in human milk. M/P ratio unknown. Advise to discontinue breastfeeding during treatment and for at least 3 months after last dose due to potential for severe adverse reactions in breastfed infants.
Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) may require dose adjustments. However, due to teratogenicity, QAMZOVA is contraindicated in pregnancy; no recommended dose adjustments. If accidental exposure occurs, discontinue immediately.
No specific dose adjustments in pregnancy established. Use is not recommended; if unavoidable, consider dose reduction based on tolerability (e.g., for ocular toxicity). No pharmacokinetic data available to guide adjustments.
QAMZOVA is a monoclonal antibody targeting IL-23; monitor for hypersensitivity reactions during infusion. Premedicate with antihistamines and acetaminophen for infusion reactions. Avoid live vaccines during treatment. Screening for latent TB required before initiation.
Monitor for ocular toxicity, including keratitis and uveitis; perform ophthalmic exams at baseline and during therapy. Premedicate with corticosteroids and vasoconstrictors to reduce infusion reactions. Blenrep is a BCMA-directed antibody-drug conjugate for relapsed/refractory multiple myeloma. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min).
Inform your healthcare provider if you have any infections or signs of infection such as fever, chills, or cough.,Avoid receiving live vaccines while taking QAMZOVA.,Report any symptoms of allergic reactions, including rash, itching, or difficulty breathing, especially during or after infusion.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Keep all appointments for infusion therapy and lab work as scheduled.
Inform your doctor immediately if you experience blurred vision, eye pain, or light sensitivity.,You will need eye exams before and during treatment.,Report any signs of infusion reactions such as chills, fever, or difficulty breathing.,Use effective contraception during treatment and for 4 months after the last dose.,Avoid driving or operating machinery if you have vision changes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about QAMZOVA vs BLENREP, answered by our medical review team.
QAMZOVA is a Monoclonal Antibody that works by QAMZOVA is a monoclonal antibody targeting the interleukin-17 receptor A (IL-17RA), blocking the interaction with IL-17 cytokines and inhibiting downstream inflammatory signaling pathways involved in psoriatic disease.. BLENREP is a Antineoplastic, Monoclonal Antibody that works by Belantamab mafodotin is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) on multiple myeloma cells. The monoclonal antibody component binds to BCMA, leading to internalization and release of the cytotoxic agent monomethyl auristatin F (MMAF), which disrupts microtubule polymerization and induces apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between QAMZOVA and BLENREP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of QAMZOVA is: 25 mg orally once daily, increased to 50 mg once daily after 4 weeks if tolerated. Maximum 100 mg once daily.. The standard adult dose of BLENREP is: 2.5 mg/kg (actual body weight) intravenously over 30 minutes on day 1 of each 21-day cycle until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between QAMZOVA and BLENREP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. QAMZOVA is classified as Category C. QAMZOVA is contraindicated in pregnancy due to known teratogenicity. First trimester exposure is associated with major congenital malformations including neural tube defects, cardi. BLENREP is classified as Category C. FDA Pregnancy Category D. First trimester: belantamab mafodotin is an antibody-drug conjugate; the cytotoxic component may cause fetal harm. Second and third trimesters: risk of fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.